Stephen Poor
Seminars
Wednesday 20th January 2027
Panel Discussion: Improving Long-Acting Therapy Success Rates Through Real-World Lessons in Durability, Translation & Development
12:30 pm
- Join experienced developers and researchers of long-acting ocular therapies to explore lessons from ongoing development to avoid common pitfalls and accelerate development
- Understand why promising durability data often fails to translate from preclinical studies into clinical success and learn how to generate more predictive evidence earlier in development
- Learn how to overcome formulation, delivery, inflammation, and safety challenges while improving durability, efficacy, and patient experience
- Discuss practical strategies for managing development risk, investment timelines, and key decision points to improve long-term clinical and commercial success
Thursday 21st January 2027
Roundtable Discussion: Proving Long-Term Therapeutic Value Through Endpoint Selection & Clinical Trial Design
1:15 pm
Join breakout roundtables led by expert moderators to debate key questions, capture consensus and differing views, then reconvene as moderators share insights and spark wider audience debate.
- Discuss how the field should evolve beyond traditional visual acuity measures by identifying functional endpoints that better reflect real-world patient experience, including contrast sensitivity, low-light vision, and other measures of meaningful visual function
- Share experiences validating novel endpoints with regulatory agencies, exploring the evidence packages, study designs, and clinical data required to support acceptance of new outcome measures in future retinal trials
- Explore how predictive biomarkers, advanced imaging analytics, and emerging endpoint strategies can improve patient selection, accelerate development timelines, and generate stronger evidence for regulatory approval and long-term therapeutic value
- Debate which functional endpoints should be prioritised in future retinal studies, how they should be implemented within clinical trials, and what level of change represents a clinically meaningful benefit for patients
